In addition to immunotherapy, the adoptive transfer of cytotoxic T-lymphocytes (CTLs) specific to EBV that target LMP1, LMP2, and EBNA1 viral antigens has been recognized as potential approach for endemic NPC patients [44]. Here, PSMB9 is linked to nasopharyngeal carcinoma.